Last reviewed · How we verify
AZD6244 Dosing Period 2
MEK inhibitor
MEK inhibitor Used for Non-small cell lung cancer.
At a glance
| Generic name | AZD6244 Dosing Period 2 |
|---|---|
| Also known as | AZD6244 |
| Sponsor | AstraZeneca |
| Drug class | MEK inhibitor |
| Target | MEK1 and MEK2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AZD6244 is a potent and selective inhibitor of MEK1 and MEK2, enzymes that are key regulators of the MAPK/ERK signaling pathway.
Approved indications
- Non-small cell lung cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas (PHASE1)
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (PHASE1)
- AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies (PHASE1)
- A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD6244 Dosing Period 2 CI brief — competitive landscape report
- AZD6244 Dosing Period 2 updates RSS · CI watch RSS
- AstraZeneca portfolio CI